FATE - Company ID 0001434316
The table below shows FATE THERAPEUTICS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.65M | $13.63M | $63.53M | $96.30M | $55.85M | $31.43M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $107.83M | $135.00M | $172.60M | $320.45M | $215.52M | $125.62M |
| SG&A |
FATE THERAPEUTICS INC reported annual revenue of $6.65M for fiscal year 2025. That is down 51.2% from $13.63M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $4.40M (FY 2016) to $6.65M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $46.52M |
| $74.17M |
| $81.45M |
| $84.23M |
| $57.32M |
| $33.90M |
| Operating income | -$147.70M | -$210.28M | -$190.51M | -$308.39M | -$216.99M | -$128.09M |
| Income tax | $2.00K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$136.31M | -$186.26M | -$160.93M | -$281.72M | -$212.15M | -$173.39M |
| EPS (diluted) | -$1.15 | -$1.64 | -$1.64 | -$2.91 | -$2.24 | -$2.10 |